Compass Pathways has completed its submission of an NDA to the FDA for COMP360 psilocybin for treatment-resistant depression.
|Slideshows|December 2, 2019
Year in Review: 2019 Special Reports in Psychiatry
Author(s)Heidi Anne Duerr, MPH, Laurie Martin
As varied as the field of psychiatry itself, our Special Report collections covered issues such as eating disorders, traumatic brain injury, practice management, schizophrenia and depression, complex medical comorbidities, and more. Here's a sampling.
Advertisement
Advertisement
Related to this article
Why D2 blockade alone falls short in schizophrenia, and what neurotransmitter, genetic and neuroimaging research means for treatment-resistant patients.
GLP-1 drugs enter psychiatry, curbing antipsychotic weight gain while raising new questions about addiction, mood, eating disorders, and culture.
Alkermes launches a phase 2 trial of oral orexin-2 agonist ALKS 7290 to boost antidepressant response in major depressive disorder, assessing safety and symptom relief.
New automated connectomics maps synapses across circuits, revealing how inhibitory neuron subtypes shape decision-making and may explain circuit dysfunction in psychiatric disorders.
The evidence points toward an overall protective effect in adult cohorts and no increase in completed suicide in younger populations.
Explore evolving ethical challenges of long-acting injectable antipsychotics, weighing relapse prevention against coercion, stigma, incentives, and racial equity in clinical practice.
Advertisement
Advertisement
Trending on Psychiatric Times
1
Lumateperone Shows Significant and Rapid Improvement in Bipolar Mania
2
NDA Submission Complete: COMP360 Psilocybin for Treatment-Resistant Depression
3
New National Guidance for Managing Medetomidine Intoxication and Withdrawal
4
Updates on CTx-1301, NDA Resubmission After FDA Complete Response Letter
5